Statin use and the risk of developing diabetes: a network meta-analysis
- PMID: 27277934
- DOI: 10.1002/pds.4020
Statin use and the risk of developing diabetes: a network meta-analysis
Abstract
Purpose: Randomized controlled trials have shown mixed findings regarding the association of statins and diabetes. This systematic literature review and network meta-analysis (NMA) was performed to update evidence on this association to possibly assist clinicians in making more informed treatment choices.
Methods: We identified studies relevant to our NMA by performing study searches in databases like Embase, Cochrane, and PubMed, published between August 2010 and June 2014. Pre-2010 studies were identified from bibliography of previously published meta-analyses. Unpublished study data were found from clinicaltrial.gov. Data synthesis was performed by pairwise meta-analysis and NMA within a Frequentist framework.
Results: Twenty nine trials in which 1 63 039 participants had been randomized were included in this review; among these 1 41 863 were non-diabetic patients. The direct meta-analysis showed that statins, as a class, significantly increased the likelihood of developing diabetes by 12% (pooled OR 1.12; 95%CI 1.05-1.21; I2 36%; p = 0.002; 18 RCTs). In the NMA, atorvastatin 80 mg was associated with a highest risk of diabetes, with OR of 1.34 (95%CI 1.14-1.57) followed by rosuvastatin (OR: 1.17; 95%CI: 1.02-1.35). The ORs (95%CIs) for simvastatin 80 mg, simvastatin, atorvastatin, pravastatin, lovastatin and pitavastatin were 1.21 (0.99-1.49), 1.13 (0.99-1.29), 1.13 (0.94-1.34), 1.04 (0.93-1.16), 0.98 (0.69-1.38) and 0.74 (0.31-1.77), respectively. High-dose atorvastatin increased the odds of developing diabetes even when compared with pravastatin, simvastatin and low-dose atorvastatin in the NMA.
Conclusions: Based on the results, statins, as a class, increased the risk of diabetes significantly in the pairwise meta-analysis. Overall, there appears to be a small increased risk of incident diabetes, particularly with more intensive statin therapy, although more data would be valuable to increase the robustness of this interpretation, given that the lower confidence intervals of our study analyses are close to, or just crossing one. Copyright © 2016 John Wiley & Sons, Ltd.
Keywords: cardiovascular disease; meta-analysis; network meta-analysis; pharmacoepidemiology; safety; statins; systematic review; type 2 diabetes.
Copyright © 2016 John Wiley & Sons, Ltd.
Comment in
-
Statins and diabetes: is there any difference between the different statins?Pharmacoepidemiol Drug Saf. 2017 Oct;26(10):1296-1297. doi: 10.1002/pds.4296. Pharmacoepidemiol Drug Saf. 2017. PMID: 28967200 No abstract available.
Similar articles
-
Associations between statins and adverse events in primary prevention of cardiovascular disease: systematic review with pairwise, network, and dose-response meta-analyses.BMJ. 2021 Jul 14;374:n1537. doi: 10.1136/bmj.n1537. BMJ. 2021. PMID: 34261627 Free PMC article.
-
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.Am Heart J. 2019 Apr;210:18-28. doi: 10.1016/j.ahj.2018.12.007. Epub 2019 Jan 10. Am Heart J. 2019. PMID: 30716508
-
Statin Use and Cancer Incidence in Patients with Type 2 Diabetes Mellitus: A Network Meta-Analysis.Gastroenterol Res Pract. 2018 Sep 4;2018:8620682. doi: 10.1155/2018/8620682. eCollection 2018. Gastroenterol Res Pract. 2018. PMID: 30254671 Free PMC article. Review.
-
Statin therapy on glycemic control in type 2 diabetic patients: A network meta-analysis.J Clin Pharm Ther. 2018 Aug;43(4):556-570. doi: 10.1111/jcpt.12690. Epub 2018 May 7. J Clin Pharm Ther. 2018. PMID: 29733433
-
Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials.Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):390-9. doi: 10.1161/CIRCOUTCOMES.111.000071. Epub 2013 Jul 9. Circ Cardiovasc Qual Outcomes. 2013. PMID: 23838105 Review.
Cited by
-
Does Rosuvastatin/Ezetimibe Combination Therapy Offer Potential Benefits for Glucose Metabolism beyond Lipid-Lowering Efficacy in T2DM?Diabetes Metab J. 2024 May;48(3):387-389. doi: 10.4093/dmj.2024.0168. Epub 2024 May 22. Diabetes Metab J. 2024. PMID: 38802118 Free PMC article. No abstract available.
-
3. Prevention or Delay of Diabetes and Associated Comorbidities: Standards of Care in Diabetes-2024.Diabetes Care. 2024 Jan 1;47(Suppl 1):S43-S51. doi: 10.2337/dc24-S003. Diabetes Care. 2024. PMID: 38078581 Review.
-
The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study.Diabetes Metab J. 2023 Nov;47(6):818-825. doi: 10.4093/dmj.2023.0171. Epub 2023 Nov 24. Diabetes Metab J. 2023. PMID: 38043782 Free PMC article. Clinical Trial.
-
Statins and risk of type 2 diabetes: mechanism and clinical implications.Front Endocrinol (Lausanne). 2023 Sep 19;14:1239335. doi: 10.3389/fendo.2023.1239335. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37795366 Free PMC article. Review.
-
Can acetate via FFA receptors contribute to the diabetogenic effect of statins?Naunyn Schmiedebergs Arch Pharmacol. 2024 Feb;397(2):1245-1248. doi: 10.1007/s00210-023-02647-7. Epub 2023 Aug 29. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 37642662 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical